Background In the current coronavirus health crisis, inhaled bronchodilators(IB) have been suggested as a possible treatment for patients hospitalized. Patients with evidence of Covid-19 pneumonia worldwide have been prescribed these medications as part of therapy for the disease, an indication for which this medications could be ineffective taken on account the pathophysiology and mechanisms of disease progression. Objective The main objective was to evaluate whether there is an association between IB use and length of stay. Primary end points were the number of days that a patient stayed in the hospital and death as a final event in a time to event analysis. Pneumonia severity, oxygen requirement, involved drugs, comorbidity, historical or current respiratory diagnoses and other drugs prescribed to treat coronavirus pneumonia were also evaluated. Methods A descriptive, observational, cross-sectional study was performed in this tertiary hospital in Madrid (Spain). Data were obtained regarding patients hospitalized with Covid-19, excluding those who were intubated. The primary and secondary outcomes such as duration of hospitalization and death were compared in patients who received IB with those in patients who did not. Results 327 patients were evaluated, mean age was 64.4±15.8 years. Median length of hospitalization stay was 10 days. Of them 292 (89.3%) overcame the disease, the remaining 35 died. Patients who had received IB did not have less mortality rate (odds ratio 0.839; 95% CI: 0.401 to 1.752) and less hospitalization period when compared with patients who did not received IB (odds ratio 1.280; 95% CI: 0.813 to 2.027). There was no significant association between IB use and recovery or death. Hypertension and diabetes were the most common comorbidities. The prevalence of chronic respiratory disease in our cohort was low (21.1%). Anticholinergics were the IB more frequently prescribed for Covid-19 pneumonia. Better response in patients treated with inhaled corticosteroids was not observed. Conclusion Off-label indication of inhaled-bronchodilators for Covid-19 patients are common in admitted patients. Taken on account our results, the use of IB for coronavirus pneumonia apparently is not associated with a significantly patient´s improvement. Our study confirms the hypothesis that inhaled bronchodilators do not improve clinical outcomes or reduce the risk of Covid-19 mortality. This could be due to the fact that the virus mainly affects the lung parenchyma and the pulmonary vasculature and probably not the airway. More researches are necessary in order to fill the gap in evidence for this new indication.
BackgroundMedication errors are common in neonatal units. Errors with potential to cause harm are more likely to occur here due to vulnerability of this population and the complexity of calculations for prescribing and preparing their medications. Errors with high alert medications (HAM) in neonatal units have been reported. These errors bear a heightened risk of causing significant patient harm. The incidence of errors is variable among studies. Having knowledge of your own HAM utilisation rate could help organisations to prioritise safe medication practices.PurposeTo analyse the use of HAM in a neonatal unit as a tool to prioritise patient safety practices.Material and methodsAn observational retrospective study was conducted in 2015 (12 months) in the neonatal unit of a university tertiary hospital. Recorded data of admissions, hospital stays and HAM consumption were analysed. The classification of HAM was according to the ISMP list and high risk drug list adapted to the neonatal or paediatric population (Cotrina et al, 2013).ResultsDuring the study period 1470 admissions and 21 611 stays were registered (14.7 stays per patient). A total of 311 different drugs were used, 23.2% (n=72) were HAM, 11 of these HAM (15.3%) being exclusively on the paediatrics list. 214 607 units were consumed, 11% were HAM (n=23 550). The main HAM detected were: antithrombotics/anticoagulants/heparins (20%), sterile water 500 mL (19%), acetaminophen (13%), general anaesthetics (11%, mainly fentanyl), antibiotics (10%, mainly vancomycin), adrenergic agonists (7%), adrenergic antagonists (3%), opioids (3%), hypertonic glucose (3%) and antiepileptic drugs (3%). The remaining 8% corresponded to: antihypertensives, neuromuscular blocking agents, inotropics, sedatives, electrolytes, antiarrhythmics and insulin. All of these drugs are frequently involved in published medication errors. General safe practices were already implemented in our hospital: protocols, training sessions and courses, summary charts for drug preparation, a dose calculator and a patient safety multidisciplinary group. Specific additional safe practices should be implemented for the HAM most frequently used.ConclusionSpecific strategies in the safe use of antithrombotics, anticoagulants and heparins, sterile water, acetaminophen, fentanyl and vancomycin must be implemented. This is critical in neonatal units, where the use of these HAM is more common and the risk of harm is higher.References and/or acknowledgementsAn Pediatr (Barc)2013;79:360–6.No conflict of interest
BackgroundTreatment with regorafenib is an alternative thirdline therapy for patients with metastatic colon cancer. This new treatment option was marketed in 2013, so it should be checked if the efficacy and safety in routine clinical practice are equivalent to those reported in pivotal trials.PurposeTo assess the efficacy and safety of regorafenib in the treatment of metastatic colon cancer in routine clinical practice in a tertiary hospital.Material and methodsThis was an observational, descriptive, retrospective study. All patients with metastatic colon cancer treated with regorafenib until June 2016 were included. Data were recorded from computerised clinical history and pharmaceutical dispensing software. The following variables were collected: age, gender, therapeutic indication, overall survival(OS), progression free survival(PFS), adverse reactions and dose reduction. The primary efficacy endpoint was OS and the secondary efficacy endpoint was PFS. For safety profile assessment, adverse reactions were studied.Results10 patients, 6 (60%) men and 4 (40%) women, were studied. Mean age was 60.8 years. All patients were diagnosed with metastatic colon cancer. Mean OS was 5.25 months and mean PFS was 2.55 months. Notified adverse reactions were: hand–foot syndrome (4), diarrhoea (2), asthenia (6), decreased intake (4), mucositis (2) and emetic syndrome (2). All patients had at least one adverse event and 80% required a full dose reduction for toxicity and/or poor tolerance.ConclusionThe results of this efficacy study of regorafenib in metastatic colon cancer therapy in routine clinical practice were inferior to those reported in pivotal trials (6.4 months OS in CORRECT or 8.8 months in CONCUR vs 5.25 months). The safety profile was similar to that described in the data sheet but the frequency of patients requiring dose reduction (80%) was higher than expected. In conclusion, comparing the efficacy of older alternatives (regorafenib PFS 1.9 months, panitumumab PFS 1.9 months, cetuximab PFS 3.7 months, best supportive care PFS 1.2 months), the use of an alternative in thirdline treatment for metastatic colon cancer should be based on its safety profile and patient tolerance.No conflict of interest
BackgroundThe use of psychiatric agents in hospitals increases the complexity of pharmacotherapy and the risk of drug–drug interactions.PurposeTo assess the frequency and clinical relevance of interactions associated with the use of antipsychotics, anxiolytics, antidepressants and sedative/hypnotics in a hospital.Material and methodsCross-sectional observational study in which the treatment of adult patients admitted to a general hospital (1,350 beds) was reviewed. The investigators, using a computerised physician order entry program, evaluated pharmacotherapy of inpatients involving antipsychotics, anxiolytics, antidepressants and sedatives/hypnotics. They assessed drug-drug interactions and their clinical significance as described in the literature. Reference sources were the Micromedex database and the Spanish Society of Hospital Pharmacist’s professional guide to drug interactions.ResultsTreatment of 393 patients was analysed. Of these, 179 (45.5%) were prescribed one of the drugs studied; 53.6% were female and 46.4% male with mean age 65 (SD ± 17.7) years. The average number of drugs prescribed per patient was 12 (SD ± 4.41). A total of 221 drug interactions was detected (9.5% pharmacokinetic, 90.5% pharmacodynamic), affecting 70.4% of patients. A total of 42.8% were due to prescription of antipsychotics, 31.1% due to antidepressants, 18.5% to anxiolytics and 7.6% to hypnotics/sedatives. The medical specialties involved were surgery (22.4%), oncology (11.1%), cardiology (8.9%), internal medicine (8.9%) and psychiatry (8.4%). Based on clinical significance, 47.5% of interactions were severe, 25.3% moderate and 27.1% mild. Potential interactions with significant clinical effects were haloperidol-tramadol (increased seizure risk), escitalopram-low molecular weight heparin (increased risk of bleeding) and midazolam-morphine (increased sedation). Three contraindicated combinations were detected: escitalopram-metoclopramide for increased QT interval, linezolid-amitriptyline for serotonin syndrome and risperidone-metoclopramide for neuroleptic syndrome and extrapyramidal reactions.ConclusionPrescription of antipsychotic drugs, antidepressants, anxiolytics and sedatives/hypnotics to inpatients is very common. These drugs cause numerous drug interactions, which can potentially have serious consequences for hospitalised patients.References and/or acknowledgementsPsychiatric DepartmentNo conflict of interest.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.